ITGR:NYE-Integer Holdings Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 125.66

Change

0.00 (0.00)%

Market Cap

USD 0.84B

Volume

0.64M

Analyst Target

USD 100.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Integer Holdings Corp is the medical device outsource manufacturer serving the energy, military, and environmental markets. The Company's brands include Greatbatch Medical, Lake Region Medical and Electrochem.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-04 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-0.22 (-0.17%)

USD 220.05B
MDT Medtronic PLC

-1.40 (-1.65%)

USD 106.32B
STE STERIS plc

-0.51 (-0.23%)

USD 22.11B
ZBH Zimmer Biomet Holdings Inc

-11.90 (-11.62%)

USD 20.08B
SNN Smith & Nephew SNATS Inc

-0.25 (-0.87%)

USD 11.31B
PEN Penumbra Inc

-2.87 (-0.97%)

USD 10.73B
GMED Globus Medical

-1.41 (-1.96%)

USD 9.77B
BIO Bio-Rad Laboratories Inc

+3.85 (+1.63%)

USD 6.94B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 6.39B
GKOS Glaukos Corp

-0.75 (-0.86%)

USD 5.15B

ETFs Containing ITGR

PSCH Invesco S&P SmallCap Heal.. 2.92 % 0.29 %

-0.87 (-0.33%)

USD 0.15B
SAWS AAM Sawgrass U.S. Small C.. 2.39 % 0.00 %

-0.06 (-0.33%)

USD 0.90M
RFLR Innovator ETFs Trust 0.27 % 0.00 %

-0.02 (-0.33%)

USD 0.02B
JELS:LSE 0.00 % 0.00 %

N/A

N/A
JLES:LSE 0.00 % 0.00 %

N/A

N/A
JLSP:LSE 0.00 % 0.00 %

N/A

N/A
JPQE:F 0.00 % 0.00 %

N/A

N/A
JPQE:XETRA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.18% 62% D 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.18% 62% D 33% F
Trailing 12 Months  
Capital Gain 12.93% 67% D+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.93% 67% D+ 75% C
Trailing 5 Years  
Capital Gain 74.41% 83% B 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.41% 83% B 56% F
Average Annual (5 Year Horizon)  
Capital Gain 17.19% 71% C- 81% B-
Dividend Return 17.19% 71% C- 79% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.09% 60% D- 34% F
Risk Adjusted Return 61.22% 97% N/A 75% C
Market Capitalization 0.84B 62% D 76% C+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 34.41 55% 17%
Price/Book Ratio 2.52 50% 33%
Price / Cash Flow Ratio 19.89 24% 16%
Price/Free Cash Flow Ratio 16.53 38% 21%
Management Effectiveness  
Return on Equity 7.72% 75% 50%
Return on Invested Capital 7.14% 72% 54%
Return on Assets 4.64% 72% 72%
Debt to Equity Ratio 60.53% 20% 55%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector